4//SEC Filing
KIRSKE DAVID 4
Accession 0001628280-25-040440
CIK 0001501697other
Filed
Aug 13, 8:00 PM ET
Accepted
Aug 14, 8:31 PM ET
Size
9.7 KB
Accession
0001628280-25-040440
Insider Transaction Report
Form 4
KIRSKE DAVID
Chief Financial Officer
Transactions
- Award
Common Stock
2025-08-14+193,254→ 193,254 total - Award
Stock Option (right to buy)
2025-08-12+1,073,249→ 1,073,249 totalExercise: $1.42Exp: 2035-08-12→ Common Stock (1,073,249 underlying) - Award
Stock Option (right to buy)
2025-08-14+352,800→ 352,800 totalExercise: $3.14Exp: 2035-08-14→ Common Stock (352,800 underlying)
Footnotes (2)
- [F1]Represents restricted stock units (RSUs) granted to the Reporting Person. One third of the RSUs shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive quarter thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date and contingent upon approval of the grant at the Issuer's 2026 Annual Meeting of Stockholders.
- [F2]One half of the shares subject to the option shall vest on February 12, 2026, with the remainder vesting in equal installments in each successive month thereafter for a period of 12 months, subject to the Reporting Person continuing to provide services through each such date; provided that one half of the shares subject to the option shall vest immediately upon achievement of certain performance-based milestones prior to February 12, 2026.
Documents
Issuer
X4 Pharmaceuticals, Inc
CIK 0001501697
Entity typeother
Related Parties
1- filerCIK 0001276750
Filing Metadata
- Form type
- 4
- Filed
- Aug 13, 8:00 PM ET
- Accepted
- Aug 14, 8:31 PM ET
- Size
- 9.7 KB